Carna Biosciences Yönetim

Yönetim kriter kontrolleri 2/4

Carna Biosciences CEO'su Kohichiro Yoshino, Apr2003 tarihinde atandı, in görev süresi 21.58 yıldır. şirketin hisselerinin 1.75% doğrudan sahiptir ve bu hisselerin değeri ¥ 105.18M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 12.8 yıl ve 6.8 yıldır.

Anahtar bilgiler

Kohichiro Yoshino

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	21.6yrs
CEO sahipliği	1.7%
Yönetim ortalama görev süresi	12.8yrs
Yönetim Kurulu ortalama görev süresi	6.8yrs

Son yönetim güncellemeleri

Recent updates

Carna Biosciences, Inc. (TSE:4572) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Aug 06

What Carna Biosciences, Inc.'s (TSE:4572) P/S Is Not Telling You

Apr 17

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Apr 11

How Much Did Carna Biosciences'(TYO:4572) Shareholders Earn From Share Price Movements Over The Last Five Years?

Feb 17

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Dec 26

CEO

Kohichiro Yoshino (75 yo)

21.6yrs

Görev süresi

Dr. Kohichiro Yoshino, Ph. D. is Independent Outside Director of Kringle Pharma, Inc since December 2018. Dr. Yoshino serves as the Chief Executive Officer of Carna Biosciences, Inc. He has been President...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kohichiro Yoshino	CEO, President & Representative Director	21.6yrs	Veri yok	1.75% ¥ 105.2m
Emi Yamamoto	GM of Business Mgt.	9.2yrs	Veri yok	0.29% ¥ 17.2m
Masaaki Sawa	GM of Research & Development Division	no data	Veri yok	0.56% ¥ 33.4m
Norio Aikawa	Head of Drug Discovery & Support Business	16.3yrs	Veri yok	0.53% ¥ 32.1m
Akinori Arimura	GM of Clinical Development	5.8yrs	Veri yok	0.086% ¥ 5.2m

12.8yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim: 4572 'un yönetim ekibi deneyimli ve deneyimlidir ( 12.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kohichiro Yoshino	CEO, President & Representative Director	21.6yrs	Veri yok	1.75% ¥ 105.2m
Emi Yamamoto	GM of Business Mgt.	8.7yrs	Veri yok	0.29% ¥ 17.2m
Masaaki Sawa	GM of Research & Development Division	9.7yrs	Veri yok	0.56% ¥ 33.4m
Norio Aikawa	Head of Drug Discovery & Support Business	20.7yrs	Veri yok	0.53% ¥ 32.1m
Akinori Arimura	GM of Clinical Development	1.7yrs	Veri yok	0.086% ¥ 5.2m
Tsuguo Ogasawara	Independent Outside Director	4.8yrs	Veri yok	0.026% ¥ 1.6m
Atsuo Arita	Independent Outside Director	4.8yrs	Veri yok	0.042% ¥ 2.5m
Teruo Takayanagi	Independent Outside Director	9.7yrs	Veri yok	0.0058% ¥ 346.5k
Takao Matsui	Independent Outside Director	4.8yrs	Veri yok	Veri yok
Kaoru Suzuki	Independent Outside Director	less than a year	Veri yok	Veri yok

6.8yrs

Ortalama Görev Süresi

75yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 4572 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.8 yıldır).

Carna Biosciences Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Carna Biosciences, Inc., Annual General Meeting, Mar 26, 2024

Carna Biosciences, Inc., Annual General Meeting, Mar 24, 2023

Insufficient new directors

Carna Biosciences, Inc., Annual General Meeting, Mar 24, 2022

Carna Biosciences, Inc., Annual General Meeting, Mar 25, 2021

Recent updates

Third quarter 2024 earnings released: JP¥27.37 loss per share (vs JP¥20.13 loss in 3Q 2023)

Carna Biosciences, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Carna Biosciences, Inc. (TSE:4572) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

New major risk - Share price stability

Carna Biosciences, Inc. to Report Q2, 2024 Results on Aug 07, 2024

New minor risk - Shareholder dilution

First quarter 2024 earnings released: JP¥23.21 loss per share (vs JP¥32.77 loss in 1Q 2023)

What Carna Biosciences, Inc.'s (TSE:4572) P/S Is Not Telling You

Carna Biosciences, Inc. to Report Q1, 2024 Results on May 10, 2024

Full year 2023 earnings released: JP¥68.57 loss per share (vs JP¥99.07 loss in FY 2022)

Carna Biosciences, Inc., Annual General Meeting, Mar 26, 2024

Carna Biosciences, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024

Third quarter 2023 earnings released: JP¥20.13 loss per share (vs JP¥31.91 loss in 3Q 2022)

Carna Biosciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Market cap size

Second quarter 2023 earnings released: JP¥21.43 loss per share (vs JP¥25.25 loss in 2Q 2022)

Carna Biosciences, Inc. to Report Q2, 2023 Results on Aug 07, 2023

First quarter 2023 earnings released: JP¥32.77 loss per share (vs JP¥1.12 loss in 1Q 2022)

Full year 2022 earnings released: JP¥99.07 loss per share (vs JP¥42.06 loss in FY 2021)

Full year 2022 earnings released: JP¥99.07 loss per share (vs JP¥42.06 loss in FY 2021)

Carna Biosciences, Inc., Annual General Meeting, Mar 24, 2023

Insufficient new directors

Carna Biosciences, Inc. to Report Q4, 2022 Results on Feb 10, 2023

Carna Biosciences, Inc. announced that it has received ¥11.209315 million in funding from Cantor Fitzgerald & Co.

Carna Biosciences, Inc. announced that it expects to receive ¥11.209315 million in funding from Cantor Fitzgerald & Co.

Third quarter 2022 earnings released: JP¥31.91 loss per share (vs JP¥31.70 loss in 3Q 2021)

Carna Biosciences, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Second quarter 2022 earnings released: JP¥25.25 loss per share (vs JP¥39.45 loss in 2Q 2021)

Carna Biosciences, Inc. to Report Q2, 2022 Results on Aug 05, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations

Carna Biosciences, Inc. to Report Q1, 2022 Results on May 10, 2022

Full year 2021 earnings: EPS misses analyst expectations

Carna Biosciences, Inc., Annual General Meeting, Mar 24, 2022

Consensus revenue estimates increase by 40%

Third quarter 2021 earnings released: JP¥31.70 loss per share (vs JP¥20.32 loss in 3Q 2020)

Consensus forecasts updated

Second quarter 2021 earnings released: JP¥39.45 loss per share (vs JP¥17.31 loss in 2Q 2020)

First quarter 2021 earnings released: JP¥23.06 loss per share (vs JP¥15.22 loss in 1Q 2020)

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Full year 2020 earnings released: JP¥90.33 loss per share (vs JP¥76.03 profit in FY 2019)

How Much Did Carna Biosciences'(TYO:4572) Shareholders Earn From Share Price Movements Over The Last Five Years?

Full year 2020 earnings released: JP¥90.33 loss per share (vs JP¥76.03 profit in FY 2019)

Revenue beats expectations, earnings disappoint

Carna Biosciences, Inc., Annual General Meeting, Mar 25, 2021

New 90-day high: JP¥1,433

Carna Biosciences, Inc. to Report Fiscal Year 2020 Results on Feb 12, 2021

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

New 90-day low: JP¥1,148

Third quarter 2020 earnings released: JP¥20.32 loss per share

New 90-day low: JP¥1,294

Carna Biosciences, Inc. to Report Q3, 2020 Results on Nov 09, 2020

New 90-day low - JP¥1,371

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş